Telemetry Investments’s Gain Therapeutics GANX Stock Holding History

Telemetry Investments’s Portfolio GANX Stock Details GANX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	$385K	Sell	123,000 -27,000	-18%	-$84.4K	0.61%	44
2022 Q3	$489K	Sell	150,000 -10,000	-6%	-$37.6K	0.63%	49
2022 Q2	$576K	Sell	160,000 -80,000	-33%	-$276K	0.68%	43
2022 Q1	$979K	Buy	240,000 +88,868	+59%	+$372K	1.55%	14
2021 Q4	$807K	Buy	151,132 +54,900	+57%	+$379K	1.04%	23
2021 Q3	$716K	Buy	96,232 +65,939	+218%	+$551K	0.96%	38
2021 Q2	$303K	Buy	+30,293	New	+$342K	0.42%	76

Other funds holding GANX

Greenlight Capital New York $2.05B AUM 78.75% 1-Year Est. Return

CM Management Gulf Breeze, Florida $157M AUM 60.08% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

BCM

Bridgeway Capital Management Houston, Texas $5.69B AUM 60.64% 1-Year Est. Return

PCM

Prelude Capital Management New York $1.37B AUM 71.68% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $672B AUM 33.48% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

RJA

Raymond James & Associates St Petersburg, Florida $164B AUM 33.91% 1-Year Est. Return

WAAG

Wealth Alliance Advisory Group Wichita, Kansas $691M AUM 24.37% 1-Year Est. Return

Telemetry Investments's GANX Position: Q4 2022 in Review

Telemetry Investments reduced its Gain Therapeutics (GANX) stake by 18% in Q4 2022, selling an estimated $84.4K and leaving 123,000 shares worth $385K. The position accounts for 0.61% of the portfolio, ranked #44.

Telemetry Investments first reported a position in GANX in Q2 2021 and has held it in 7 quarters since. The position peaked at $979K in Q1 2022. 20 funds tracked by Wall St. Rank hold GANX as of Q4 2022.

Telemetry Investments held 123,000 shares of Gain Therapeutics worth $385K as of Q4 2022.
Telemetry Investments sold 27,000 Gain Therapeutics shares in Q4 2022, an estimated $84.4K.
Gain Therapeutics made up 0.61% of Telemetry Investments's portfolio in Q4 2022, its #44 holding.
Telemetry Investments first reported a position in Gain Therapeutics in Q2 2021 and has held it in 7 quarters since.
Telemetry Investments's Gain Therapeutics position peaked at $979K in Q1 2022.
20 funds tracked by Wall St. Rank held Gain Therapeutics as of Q4 2022.

Based on Telemetry Investments's 13F filing for Q4 2022, filed 14 Feb 2023.